APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY
|
|
- Melvin Lang
- 5 years ago
- Views:
Transcription
1 Page 1 Somatropin INITIAL APPLICATION - growth hmone deficiency in children Growth hmone deficiency causing symptomatic hypoglycaemia, with other significant growth hmone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) diagnosed with GH < 5 mcg/l on at least two rom blood samples in the first 2 weeks of life, from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a labaty device) Height velocity < 25th percentile f age adjusted f bone age/pubertal status if appropriate over 6 12 months using the stards of Tanner Davies (1985) A current bone age is < 14 years (female patients) < 16 years (male patients) Peak growth hmone value of < 5.0 mcg per litre in response to two different growth hmone stimulation tests. In children who are 5 years older, GH testing with sex steroid priming is required If the patient has been treated f a malignancy, they should be disease free f at least one year based upon follow-up labaty radiological imaging appropriate f the malignancy, unless there are strong medical reasons why this is either not necessary appropriate Appropriate imaging of the pituitary gl has been obtained RENEWAL - growth hmone deficiency in children A current bone age is 14 years under (female patients) 16 years under (male patients) Height velocity is greater than equal to 25th percentile f age (adjusted f bone age/pubertal status if appropriate) while on growth hmone treatment, as calculated over six months using the stards of Tanner Davis (1985) Height velocity is greater than equal to 2.0 cm per year, as calculated over 6 months No serious adverse effect that the patients specialist considers is likely to be attributable to growth hmone treatment has occurred No malignancy has developed since starting growth hmone See also: INITIAL APPLICATION - Turner syndrome p2, RENEWAL - Turner syndrome p2, INITIAL APPLICATION - sht stature without growth hmone deficiency p2, RENEWAL - sht stature without growth hmone deficiency p3, INITIAL APPLICATION - sht stature due to chronic renal insufficiency p3, RENEWAL - sht stature due to chronic renal insufficiency p4, INITIAL APPLICATION - Prader-Willi syndrome p5, RENEWAL - Prader-Willi syndrome p5, INITIAL APPLICATION - adults adolescents p6 RENEWAL - adults adolescents p7 I confirm the above details are crect that in signing this fm I underst I may be audited.
2 Page 2 INITIAL APPLICATION - Turner syndrome The patient has a post-natal genotype confirming Turner Syndrome Height velocity is < 25th percentile over 6-12 months using the stards of Tanner Davies (1985) A current bone age is < 14 years RENEWAL - Turner syndrome Height velocity is greater than equal to 50th percentile f age (while on growth hmone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts) Height velocity is greater than equal to 2 cm per year, calculated over six months A current bone age is 14 years under No serious adverse effect that the specialist considers is likely to be attributable to growth hmone treatment has occurred No malignancy has developed since starting growth hmone INITIAL APPLICATION - sht stature without growth hmone deficiency The patient's height is me than 3 stard deviations below the mean f age f bone age if there is marked growth acceleration delay Height velocity is < 25th percentile f age (adjusted f bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the stards of Tanner Davies(1985) A current bone age is < 14 years under (female patients) < 16 years (male patients) The patient does not have severe chronic disease (including malignancy recognized severe skeletal dysplasia) is not receiving medications known to impair height velocity See also: RENEWAL - sht stature without growth hmone deficiency p3, INITIAL APPLICATION - sht stature due to chronic renal insufficiency p3, RENEWAL - sht stature due to chronic renal insufficiency p4, INITIAL APPLICATION - Prader-Willi syndrome p5, RENEWAL - Prader-Willi syndrome p5, INITIAL APPLICATION - adults adolescents p6 RENEWAL - adults adolescents p7 I confirm the above details are crect that in signing this fm I underst I may be audited.
3 Page 3 RENEWAL - sht stature without growth hmone deficiency Height velocity is greater than equal to 50th percentile (adjusted f bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the stards of Tanner Davies (1985) Height velocity is greater than equal to 2 cm per year as calculated over six months A current bone age is 14 years under (female patients) 16 years under (male patients) No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hmone treatment has occurred INITIAL APPLICATION - sht stature due to chronic renal insufficiency Applications only from a paediatric endocrinologist, endocrinologist renal physician on the recommendation of a paediatric endocrinologist endocrinologist. Approvals valid f 9 months. The patient's height is me than 2 stard deviations below the mean Height velocity is < 25th percentile (adjusted f bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the stards of Tanner Davies (1985) A current bone age is to 14 years under (female patients) to 16 years under (male patients) The patient is metabolically stable, has no evidence of metabolic bone disease absence of any other severe chronic disease The patient is under the supervision of a specialist with expertise in renal medicine The patient has a GFR less than equal to 30 ml/min/1.73m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l) x 40 = crected GFR (ml/min/1.73m² in a child who may may not be receiving dialysis The patient has received a renal transplant has received < 5mg/ m²/day of prednisone equivalent f at least 6 months. See also: RENEWAL - sht stature due to chronic renal insufficiency p4, INITIAL APPLICATION - Prader-Willi syndrome p5, RENEWAL - Prader-Willi syndrome p5, INITIAL APPLICATION - adults adolescents p6 RENEWAL - adults adolescents p7 I confirm the above details are crect that in signing this fm I underst I may be audited.
4 Page 4 RENEWAL - sht stature due to chronic renal insufficiency Applications only from a paediatric endocrinologist, endocrinologist renal physician on the recommendation of a paediatric endocrinologist endocrinologist. Approvals valid f 12 months. Height velocity is greater than equal to 50th percentile (adjusted f bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the stards of Tanner Davies (1985) Height velocity is greater than equal to 2 cm per year as calculated over six months A current bone age is 14 years under (female patients) 16 years under (male patients) No serious adverse effect that the patients specialist considers is likely to be attributable to growth hmone has occurred No malignancy has developed after growth hmone therapy was commenced The patient has not experienced significant biochemical metabolic deteriation confirmed by diagnostic results The patient has not received renal transplantation since starting growth hmone treatment If the patient requires transplantation, growth hmone prescription should cease befe transplantation a new application should be made after transplantation based on the above criteria See also: INITIAL APPLICATION - Prader-Willi syndrome p5, RENEWAL - Prader-Willi syndrome p5, INITIAL APPLICATION - adults adolescents p6 RENEWAL - adults adolescents p7 I confirm the above details are crect that in signing this fm I underst I may be audited.
5 Page 5 INITIAL APPLICATION - Prader-Willi syndrome The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing clinical scing criteria The patient is aged six months older A current bone age is < 14 years (female patients) < 16 years (male patients) Sleep studies overnight oximetry have been perfmed there is no obstructive sleep disder requiring treatment, if an obstructive sleep disder is found, it has been adequately treated under the care of a paediatric respiraty physician / ENT surgeon The patient is aged two years older There is no evidence of type II diabetes uncontrolled obesity defined by BMI that has increased by greater than equal to 0.5 stard deviations in the preceding 12 months The patient is aged between six months two years a though upper airway assessment is planned to be undertaken pri to treatment commencement at six to 12 weeks following treatment initiation RENEWAL - Prader-Willi syndrome Height velocity is greater than equal to 50th percentile (adjusted f bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the stards of Tanner Davies (1985) Height velocity is greater than equal to 2 cm per year as calculated over six months A current bone age is 14 years under (female patients) 16 years under (male patients) No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hmone treatment has occurred No malignancy has developed after growth hmone therapy was commenced The patient has not developed type II diabetes uncontrolled obesity as defined by BMI that has increased by greater than equal to 0.5 stard deviations in the preceding 12 months See also: INITIAL APPLICATION - adults adolescents p6 RENEWAL - adults adolescents p7 I confirm the above details are crect that in signing this fm I underst I may be audited.
6 Page 6 INITIAL APPLICATION - adults adolescents The patient has a medical condition that is known to cause growth hmone deficiency (e.g. surgical removal of the pituitary f treatment of a pituitary tumour) The patient has undergone appropriate treatment of other hmonal deficiencies psychological illnesses The patient has severe growth hmone deficiency (see notes) The patient's serum IGF-I is me than 1 stard deviation below the mean f age sex The patient has po quality of life, as defined by a sce of 16 me using the disease-specific quality of life questionnaire f adult growth hmone deficiency (QoL-AGHDA ) Note: F the purposes of adults adolescents, severe growth hmone deficiency is defined as a peak serum growth hmone level of less than equal to 3 mcg per litre during an adequately perfmed insulin tolerance test (ITT) glucagon stimulation test. Patients with one me additional anteri pituitary hmone deficiencies a known structural pituitary lesion only require one test. Patients with isolated growth hmone deficiency require two growth hmone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hmone level of less than equal to 0.4 mcg per litre. The dose of somatropin should be started at 0.2 mg daily be titrated by 0.1 mg monthly until the serum IGF-I is within 1 stard deviation of the mean nmal value f age sex; Dose of somatropin not to exceed 0.7 mg per day f male patients, 1 mg per day f female patients. At the commencement of treatment f hypopituitarism, patients must be monited f any required adjustment in replacement doses of cticosteroid levothyroxine. See also: RENEWAL - adults adolescents p7 I confirm the above details are crect that in signing this fm I underst I may be audited.
7 Page 7 RENEWAL - adults adolescents The patient has been treated with somatropin f < 12 months There has been an improvement in Quality of Life defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hmone Deficiency in Adults (QoL-AGHDA ) sce from baseline Serum IGF-I levels have been increased within ±1SD of the mean of the nmal range f age sex The dose of somatropin has not exceeded 0.7 mg per day f male patients, 1 mg per day f female patients The patient has been treated with somatropin f me than 12 months The patient has not had a deteriation in Quality of Life defined as a 6 point greater increase from their lowest QoL-AGHDA sce on treatment (other than due to obvious external facts such as external stresss) Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the nmal range f age sex (other than f obvious external facts) The dose of somatropin has not exceeded 0.7 mg per day f male patients 1 mg per day f female patients I confirm the above details are crect that in signing this fm I underst I may be audited.
General Approval Criteria for ALL Growth Hormone agents: (ALL criteria must be met)
Growth Hormone Agents Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Page 1 of 7 Preferred Agents Somatropin Pen (Norditropin ) Somatropin Pen (Nutropin AQ ) Non-Preferred
More informationClinical Standards for GH Treatment in Childhood & Adolescence.
Clinical Standards for GH Treatment in Childhood & Adolescence. The Clinical Standards for GH treatment have been produced by the Clinical Committee of the BSPED. They are evidence based where possible
More informationCircle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]
05/20/2015 Prior Authorization MERC CARE PLA (MEDICAID) Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationRequest for Prior Authorization Growth Hormone (Norditropin
Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationAPPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY
APPLICANT (stamp sticker acceptable) Page 1 Fm SA1603 Insulin Pumps INITIAL APPLICATION - permanent neonatal diabetes Applications only from a relevant specialist nurse practitioner. Approvals valid f
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationClinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION
Clinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION Date of First Issue 01/04/2015 Approved 28/01/2016 Current Issue Date 28/01/2016 Review
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)
More information2. Is the request for Humatrope? Y N [If no, skip to question 6.]
Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA Growth Hormone Agents This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.
More informationTEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN
TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First & Last Name:
More informationHUMAN GROWTH HORMONE GENOTROPIN
Drug Prior Authorization Guideline HUMAN GROWTH HORMONE GENOTROPIN (somatropin) PA9728 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes Additional Information: Medicare
More informationAetna Better Health of Virginia
Genotropin Nutropin Serostim Zomacton Humatrope Omnitrope Zorbtive somatropin Norditropin Saizen General Criteria for Approval: Omnitrope vial formulation is the preferred Growth Hormone product; consideration
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents
Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth
More informationAPPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY
Page 1 Rituximab INITIAL APPLICATION - Post-transplant The patient has B-cell post-transplant lymphoproliferative disder* To be used f a maximum of 8 treatment cycles Indications marked with * are Unapproved
More informationPrior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products
Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only Criteria: P0078 Approved: 3/2017 Reviewed: Non-Preferred Growth Hormone Products Complete/review information, sign
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT
1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti-Doping Agency International Standard for TUEs. The TUE application process
More informationGrowth Hormones DRUG.00009
Market DC Growth Hormones DRUG.00009 Override(s) Prior Authorization Quantity Limit Approval Duration WPM PAB Center: Thirty (30) day exception for recently expired (within the past 45 days) growth hormone
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other SOMATROPIN HUMATROPE GENOTROPIN NORDITROPIN NORDITROPIN FLEXPRO NORDITROPIN NORDIFLEX NUTROPIN NUTROPIN AQ OMNITROPE SAIZEN ZOMACTON 02824 BRAND ZORBTIVE BRAND SEROSTIM
More informationCIGNA HealthCare Prior Authorization Form - Growth Hormone Medications -
Pharmacy Services Phone: (800)244-6224 Fax: (800)390-9745 CIGNA HealthCare Prior Authorization Form - Growth Hormone Medications - Notice: Failure to complete this form in its entirety may result in delayed
More informationTEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only
TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First
More informationNOVO NORDISK A/S. 3. Pharmacotherapeutic group Somatropin is an endocrine hormone with metabolic and growth promoting effects. 4.
08-15 Norditropin NordiLet 10 mg/1.5 ml NOVO NORDISK A/S 1. Name of the medicinal product Norditropin NordiLet 10 mg/1.5 ml Pre-filled pen, solution for injection 2. Composition Norditropin NordiLet is
More informationGrowth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka
Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT
1. Medical Condition GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT Growth Hormone Deficiency and other indications for growth hormone therapy (adult). 2. Diagnosis A.
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton (aka. Tev-Tropin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.12 Subject: Growth Hormone Pediatric Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved
More informationGenotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Saizen,
Blue Cross Blue Shield of Vermont and The Vermont Health Plan Prior Approval Guidelines Human Growth Hormone Somatropin (Genotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Serostim, Saizen, Zomacton/TevTropin,
More informationAPPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY
The patient has increased nutritional requirements APPLICANT (stamp sticker acceptable) Page 1 Fm SA1554 Stard Supplements (Ensure; Ftisip; Isosource; Jevity; Nutrison; Osmolite; Sustagen) INITIAL APPLICATION
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 03/01/201804/01/2019 POLICY A. INDICATIONS The indications below including
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti- Doping Agency International Standard for TUEs. The TUE application process
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 12/30/201601/01/2018TBD03/01/2018 POLICY A. INDICATIONS The indications
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationAPPLICATION FOR SPECIAL AUTHORITY. Subsidy for Infliximab
APPLICATION FOR SPECIAL AUTHORITY Fm SA1778 Subsidy f Infliximab Application Categy Page Graft vs host disease - Initial application... 2 Pulmonary sarcoidosis - Initial application... 2 Previous use -
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. GROWTH HORMONE THERAPY POLICY Omnitrope is the EXCLUSIVE growth hormone covered if patient meets criteria. COVERAGE
More informationAETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents
AETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents Growth Hormone and related agents Formulary: Omnitrope vials Non-Formulary: Genotropin, Humatrope, Saizen, Serostim, Tev-Tropin,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2016-8 Program Prior Authorization/Medical Necessity Medication Human Growth Hormone: Somatropin (Genotropin *, Humatrope *, Norditropin
More informationGrowth Hormone!gents. WA.PHAR.50 Growth Hormone Agents
Growth Hormone!gents WA.PHAR.50 Growth Hormone Agents Background: Human growth hormone, also known as somatotropin, is produced in the anterior lobe of the pituitary gland. This hormone plays an important
More information0BCore Safety Profile
0BCore Safety Profile Active substance: Somatropin Pharmaceutical form(s)/strength: Powder and solvent for solution for injection, 4mg/ml, 5 mg/ml and 10 mg/ml P-RMS: FR/H/PSUR/0059/001 Date of FAR: 25.02.2013
More informationPharmacy Prior Authorization Growth Hormone- Clinical Guidelines
Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Serostim, somatropin, Zorbtive, Zomacton I. Growth Hormone Deficiency in Children and Adolescents: Note: Provider must submit chart notes
More informationOriginal Effective Date: 7/5/2007
Subject: Recombinant Human Growth Hormone: PEDIATRIC_GENETIC DISEASES with Primary Effects on Growth Turner syndrome Noonan syndrome Prader-Willi syndrome SHOX mutations DISCLAIMER Original Effective Date:
More informationPost Resuscitation Care
Princess Margaret Hospital f Children PAEDIATRIC ACUTE CARE GUIDELINE Post Resuscitation Care Scope (Staff): Scope (Area): All Emergency Department Clinicians Emergency Department This document should
More informationAPPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY
APPLICANT (stamp sticker acceptable) Page 1 Fm SA1621 Adalimumab INITIAL APPLICATION - rheumatoid arthritis Applications only from a rheumatologist. Approvals valid f 6 months. The patient has had an initial
More informationAPPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY
APPLICANT (stamp sticker acceptable) Page 1 Fm SA1620 Etanercept INITIAL APPLICATION - juvenile idiopathic arthritis Applications only from a named specialist rheumatologist. Approvals valid f 6 months.
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2018 P 1039-8 Program UnitedHealthcare Pharmacy Clinical Pharmacy Programs Prior Authorization/Notification Human Growth Hormone, Growth Stimulating Products Medication Human Growth Hormone:
More informationGH therapy in PWS (& other endocrine problems) Dr. Shankar Kanumakala Consultant Paediatrician Brighton, UK
GH therapy in PWS (& other endocrine problems) Dr. Shankar Kanumakala Consultant Paediatrician Brighton, UK Overview GH therapy Indications Specific advantages Extra precautions Case scenarios without
More informationPFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 5, 2014 Growth Hormone Adult
More informationHUMATROPE. Somatropin (rbe) for Injection Human Growth Hormone
HUMATROPE Somatropin (rbe) for Injection Human Growth Hormone NAME OF THE MEDICINE HUMATROPE (somatropin, rbe, for injection). DESCRIPTION HUMATROPE (somatropin, rbe, for injection) is a polypeptide hormone
More informationPolicy: Growth Hormones Reference Number: TCHP.PHAR.184 Effective Date: Last Review Date:
Policy: Growth Hormones Reference Number: TCHP.PHAR.184 Effective Date: 07.01.2018 Last Review Date: 04.13.2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 8, 2017 Growth Hormone Adult
More informationR ecombinant growth hormone (GH) treatment is recommended
126 ORIGINAL ARTICLE The investigation of short stature: a survey of practice in Wales and suggested practical guidelines C Evans, J W Gregory, on behalf of the All Wales Clinical Biochemistry Audit Group...
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More informationDiagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health
Diagnosing Growth Disorders PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health Content Normal pattern of growth and its variation Using growth charts Interpreting auxological
More informationPharmacy Management Drug Policy
SUBJECT: Policy POLICY NUMBER: Pharmacy-18 EFFECTIVE DATE: 08/03 LAST REVIEW DATE: 9/24/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not
More informationGrowth Hormone: Review of the Evidence
Drug Use Research & Management Program DHS Division of Medical Assistance Programs, 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Growth Hormone: Review of the Evidence
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Mecasermin (Increlex) Reference Number: CP.PHAR.150 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More information5 mg, 5.3 mg and 12 mg powder for injection with diluent (with preservative) 0.2 mg 2.0 mg powder for injection with diluent (single dose syringes)
PRODUCT INFORMATION GENOTROPIN and GENOTROPIN GoQuick 5 mg, 5.3 mg and 12 mg powder for injection with diluent (with preservative) GENOTROPIN MiniQuick 0.2 mg 2.0 mg powder for injection with diluent (single
More informationSPECIAL AUTHORITY FORMS November 2018
SPECIAL AUTHORITY FORMS Contents Panel Approvals... 4 Alimentary Tract Metabolism... 6 Blood Blood Fming Organs... 40 Cardiovascular System... 54 Dermatologicals... 67 Genito-Urinary System... 73 Hmone
More informationAPPLICATION FOR SPECIAL AUTHORITY. Subsidy for Tocilizumab
APPLICATION FOR SPECIAL AUTHORITY Fm SA1781 Subsidy f Tocilizumab Application Categy Page Cytokine release syndrome - Initial application... 2 Previous use - Initial application... 2 Rheumatoid Arthritis
More informationASY-805.1: Insulin Tolerance Test. ASY-805.2: Associated Documents. ASY-805.3: Distribution of Documents. ASY-805.4: Review of Document: a b
ASY-805.1: Insulin Tolerance Test ASY-805.2: Associated Documents a b Handbook page task print-out ASY-805.3: Distribution of Documents Copy No Number Location 1 Quality Centre 2 3.1 W232 3 3.20 W232 Laminated
More informationMonth/Year of Review: September 2013 Date of Last Review: September 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: September 20, 2018 Growth Hormone
More informationPFIZER INC. PROTOCOL TITLE: Efficacy and Safety of the Authentic Recombinant Human Somatropin Genotropin in Children with Familial Short Stature
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationOZGROW Report 2009/2010
OZGROW Report 2009/2010 GH therapy in Australia As of May 2010 there are 1636 children receiving GH treatment in Australia under the PBS. The Department of Health and Ageing s (DoHA) indication for GH
More informationShared Care Protocol. Shared Care Guideline for Growth Hormone in Adults
Shared Care Protocol Reference Number Replaces: 1.2 Issue date: 17/08/2017 Author(s)/Originator(s): (please state author name and department) Pennine Acute Hospitals NHS Trust To be read in conjunction
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Human Growth Hormone Page 1 of 57 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Human Growth Hormone Pre-Determination of Services IS REQUIRED by the Member s
More informationTechnology appraisal guidance Published: 26 May 2010 nice.org.uk/guidance/ta188
Human growth hormone (somatropin) for the treatment of growth failure in children Technology appraisal guidance Published: 26 May 2010 nice.org.uk/guidance/ta188 NICE 2017. All rights reserved. Subject
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on the Approach to Pediatric Anemia and Pallor. These podcasts are designed to give medical students an overview of key
More informationFREEDOM OF INFORMATION ACT 2000 Dudley CCG - Growth Hormone Prescribing- Ref: RFI0222
Freedom of Information Team Dudley CCG Response by email 2nd Floor, Brierley Hill Health and Social Care Centre Venture Way Brierley Hill DY5 1RU 27 th August 2015 FREEDOM OF INFORMATION ACT 2000 Dudley
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Human Growth Hormone Page 1 of 44 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Human Growth Hormone Pre-Determination of Services IS REQUIRED by the Member s
More informationPFIZER INC. PROTOCOL TITLE: Growth hormone therapy in short children after renal transplantation for chronic renal failure in Germany.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationAnkylosing spondylitis Initial PBS authority application Supporting information
Ankylosing spondylitis nitial PBS authity application Suppting infmation mptant infmation This fm must be completed by a rheumatologist with expertise in the management of ankylosing spondylitis. You must
More informationWhy is my body not changing? Conflicts of interest. Overview 11/9/2015. None
Why is my body not changing? Murthy Korada Pediatrician, Pediatric Endocrinologist Ridge Meadows Hospital Surrey Memorial Hospital None Conflicts of interest Overview Overview of normal pubertal timing
More informationEffective September 30, 2011 Please refer to the Pharmacy policy for the new coverage criteria
Effective September 30, 2011 Please refer to the Pharmacy policy for the new coverage criteria Name of Policy: Growth Hormone and Insulin Like Growth Factor-1 (IGF-1) Analogues Policy #: 067 Latest Review
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Mecasermin Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 5 Effective Date... 5/15/2017 Next
More informationGrowth Hormone Therapy Guidelines: Clinical and Managed Care Perspectives
At a Glance Review Article Practical Implications e135 Author Information e144 Full text and PDF Growth Hormone Therapy Guidelines: Clinical and Managed Care Perspectives Susan R. Rose, MD; David M. Cook,
More informationInstructions for the safe administration of gadolinium based contrast agents (GBCA). 1. PREADMINISTRATION PRECAUTIONS:
POLICY NUMBER: RM 6-18 CATEGORY: Patient Care DATE: June 2016 NEXT REVIEW DATE: April 2017 SUBJECT: PURPOSE: POLICY: Intravenous Gadolinium Based Contrast Administration To prevent complications associated
More informationThe development of a manageable medical
Developing a Rational Approach for the Use of Growth Hormone in npediatric Patients David Cook, MD; and Gary Owens, MD The development of a manageable medical policy that ensures appropriate use of recombinant
More informationCommittee Approval Date: January 19, 2015 Next Review Date: January 2016
Medication Policy Manual Policy No: dru126 Topic: Increlex, mecasermin Date of Origin: January 3, 2006 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: February
More informationHEDIS Adult. Documentation and Coding Guidelines Medical record documentation required. Measure description. Coding ICD-10: Z68.1 Z68.45, Z68.
HEDIS Adult Documentation and Guidelines 2017 description Adult BMI Assessment (ABI) Members 18 74 years of age who had an outpatient visit and whose body mass index (BMI) was documented during the measurement
More informationNon-type 1 diabetes mellitus in Canadian children
Non-type 1 diabetes mellitus in Canadian children Principal investigators Shazhan Amed, MD, FRCPC, FAAP, Division of Endocrinology, The Hospital for Sick Children, 555 University Ave, Toronto ON M5G 1X8;
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationGrowth and Puberty: A clinical approach. Dr Esko Wiltshire
Growth and Puberty: A clinical approach Dr Esko Wiltshire NOTHING TO DISCLOSE Why is this character short? Food Psychosocial factors Major Systems (+drugs) Genetic potential Perinatal Classical Hormones
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationin people with intermediate 2 or high-risk disease, AND if the company provides ruxolitinib with the discount agreed in the patient access scheme.
RUXOLITINIB INDICATION Licensed / NICE TA386 is recommended as an option f treating disease-related splenomegaly symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis),
More informationHow to approach a child with growth concern
How to approach a child with growth concern Alaa Al Nofal, MD Assistant Professor of Pediatrics Pediatric Endocrinology Sanford Children Specialty Clinic Nothing to disclose Disclosure Objectives To understand
More informationDiluent Benzyl alcohol 45 mg Meta-cresol 3.3 mg Sodium chloride 45 mg Water for injections to 1 ml Water for injections to 5 ml
PRODUCT INFORMATION ZOMACTON 4 mg and 10 mg Somatropin (rbe) 1 NAME OF THE DRUG ZOMACTON contains somatropin which is a protein having the structure (191 amino acid residues) of the major component of
More informationSomatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234)
Somatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234) Common presenting symptoms/clinical assessment: Pituitary adenomas are benign neoplasms of the pituitary gland. In patients
More informationPUBLICATIONS Abstracts and publications on the psychological data available.
Page 1 of 9 Synopsis TITLE OF TRIAL : The Effects of Biosynthetic Human Growth Hormone Treatment in the Management of Children with Familial Short Stature. Protocol B: A Comparative Evaluation of Growth
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationThese patients are typical of our Endobarrier treated patients. The ones we included here are often the ones demonstrating additional benefits over
These patients are typical of our Endobarrier treated patients. The ones we included here are often the ones demonstrating additional benefits over above weight and HbA1c. 12 months After HbA1c 109 mmol/mol
More informationClinical Policy: Somatropin (Recombinant Human Growth Hormone) Reference Number: CP.PHAR.55 Effective Date: 03/11 Last Review Date: 06/17
Clinical Policy: (Recombinant Human Growth Hormone) Reference Number: CP.PHAR.55 Effective Date: 03/11 Last Review Date: 06/17 Line of Business: Medicaid Revision Log See Important Reminder at the end
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:
0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationCo-morbidity: a summary of issues from the NCIN Site-Specific Clinical Reference Groups Dr Mick Peake
Co-morbidity: a summary of issues from the NCIN Site-Specific Clinical Reference Groups Dr Mick Peake Clinical Lead, NCIN National Clinical Lead, NHS Cancer Improvement Questionnaire to Site- Specific
More information